Stanisic S, Bertolotto A, Berto P, Di Procolo P, Morawski J. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Grhta [Internet]. 2019 Apr. 10 [cited 2024 Jul. 22];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/465